Reslizumab regulatory update

FDA’s Pulmonary-Allergy Drugs Advisory Committee will meet on Dec. 9 to discuss a BLA for IV reslizumab from Teva to reduce exacerbations, relieve symptoms and improve lung function in patients ages >...